Hi everyone! I’m reaching out to introduce myself to our Medtronic community. Thanks to those who shared messages of support and advice. Naturally, my first few months were spent getting to know the community we have the honor of serving and diving into our business.
Why Medtronic Diabetes
There are so many intersections in my career around sensor technology, controls systems, and consumer software and I’m excited to weave these threads together to make a positive impact. In terms of where tech is moving — software gives us the ability to innovate much faster, and it’s tied to the device experience.
“I’m very passionate about the digital experience and am eager to double down to enhance how we support you.”
Programs like the MiniMed™ 770G system ’s My Insights, which launches in September, provides tips to optimize therapy and our Medtronic InPen™ smart** insulin system  provides dosage recommendations via a mobile app. We’re leveraging the power of data and AI to further personalize your experience and we’re excited to increase our focus in these areas.
There are many things that have impressed me in my first 90 days but what really stands out are our employees — many of whom live with type 1 diabetes (T1D) — who are personally invested in making a difference. We have a rich heritage and enduring commitment to this community and feel very proud of the innovations we’ve delivered. Most recently, we’ve updated the user experience for our MiniMed™ 770G system  with new features like smartphone connectivity and real-time data you can share with clinicians and loved ones. We worked to make this technology available for children as young as 2, knowing this was an important feature for parents.
I had a chance to spend time with our teams and customers in Europe just before starting in this role, and it’s compelling to see the impact we’re making with this next-generation system. With the MiniMed 770G system serving as a bridge to the MiniMed™ 780G system* via a remote software upgrade when available, providing this experience to our U.S. customers is a top priority.
I know many in the U.S. are understandably eager for an update on the status of the MiniMed™ 780G system with our next-generation Guardian™ 4 Sensor. I want to share with you that we’re in active and ongoing discussions with the FDA and working through our application for approval to determine what’s needed to launch this exciting technology in the U.S. I’m committed to updating you when we know more, but right now we can’t provide a near-term timeline for FDA approval. Importantly, to ensure current and future MiniMed™ 770G system users receive access to the MiniMed™ 780G system, the software upgrade period will start when the MiniMed™ 780G system* is approved and will be offered at no charge for one year. I want to thank you for your continued patience as we advance our efforts to bring you this technology.
Extending My Deepest Gratitude
I appreciate the time you’ve taken to share your thoughts and am especially grateful for the candor. I’ll continue to engage with you here to stay close to this community. Thank you for your loyalty to Medtronic over the years.
“It’s an immense honor to serve you and we’re proud to be a part of your journey.”
Our commitment to this resilient diabetes community has endured over the past 30 years and will continue long into the future.
Let’s stay in touch! Update your communication preferences by visiting your profile in Diabetes.shop . Simply login or register your account to ensure you receive communications when and how you want to receive them.
Que Dallara joined Medtronic as EVP and President  of the Diabetes business in May of 2022. Before joining Medtronic, Que served as President and CEO of Honeywell Connected Enterprise, Honeywell’s software business. Prior to that, she was SVP and chief commercial officer leading Honeywell’s efforts in brand, strategy, marketing, sales excellence, pricing, product innovation, including enterprise software, data analytics and IoT solutions.
Information provided on this webpage applies to U.S. customers only.
*Investigational. Not approved by the FDA for any use and not commercially available in the U.S.
**Smart insulin pens connect to a mobile app to provide dosing calculations, reminders and CGM system integration.
Software Upgrade Terms and Conditions
- This program allows MiniMed™ 770G system users a software upgrade at no charge within one year from the date of this software approval. Software approval will be announced.
- Software upgrade process is subject to change. The process may result in healthcare provider office visit and may result in out-of-pocket expenses such as co-pay, depending on insurance coverage. The process may require the completion of product related training.
- This program includes the insulin pump software only. CGM products and consumables are not included in this offer.
- Warranty dates do not reset. The replacement warranty date of an insulin pump upgraded with the software will remain the same as the replacement warranty date of the initial pump purchased. Your warranty date does not impact eligibility for a software update.
- MiniMed™ pumps and software have certain labeling restrictions that may exclude certain populations, including age and type of diabetes. We recommend you consult your healthcare provider regarding your eligibility to receive the software upgrade based on the labeling of the upgrade, which may differ from the labeling of the MiniMed™ 770G pump.
- Insurance coverage and plan design varies and may impact the ability to upgrade. Coverage is contingent upon your health insurance medical policy guidelines. Restrictions and medical necessity requirements may apply.
- A valid prescription will be required for this software upgrade. All participants should consult their healthcare provider for all therapy related decisions.
- Program terms and conditions are subject to change at any time and without notice. Other restrictions may apply.
Important Safety Information: MiniMed™ 770G System With SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of ins
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safetyinformation#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information InPen
The InPen is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin and for calculating an insulin dose or carbohydrate intake based on user entered data. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient-specific criteria and targets. The InPen requires a prescription. For additional product and safety information, see User Guide and http://bit.ly/InPenSafety .